fbpx

Shop

Papilocare (7x5ml)

7 single-use cannulas of 5ml


5.00 out of 5
See Reviews

20.70 (VAT included)

Out of stock

SKU: SKU03-1.

Product is for: Cervical lesions caused by HPV Human papillomavirus (HPV) infection Papilocare Thrush (yeast and candida infection)

Explore This Product

Explore This Product

World’s first treatment to prevent and treat cervical lesions caused by human papilloma virus (HPV)

Used by over 30,000 patients in Europe since 2016; new to UK and Ireland

Women with human papilloma virus-related cervical lesions

Women with human papilloma virus who want to accelerate the eradication of the virus and prevent cervical lesions

Learn more about HPV and cervical lesions

Ingredients:

Coriolus versicolor: stimulates immune response

Neem (azadirachta indica): repairs tissues

Aloe vera: repairs tissues

Bioecolia: modulate the microbiota

Hyaluronic acid: moisturise (in niosome form)

Beta-glucan: provides anti-inflammatory and anti-oxidant effect (in niosome form)

Centella asiatica: repairs tissues (in phytosome form)

Nisome and phytosomes are innovative encapsulation forms that deliver active substances to basal and parabasal layer of the epithelium (i.e., deeper part of the tissue), where HPV is active

Learn more about natural ingredients

How it works:

Re-epithelise the transformation zone of the cervix

Rebalance the vaginal microbiota

Enhance local immune response

Repairing HPV cervical lesions in HPV patients after 3 months of Papilocare use: 70% (user) vs 40% (non-user) – statistically significant

Repairing HPV cervical lesions in high-risk HPV patients after 3 months of Papilocare use: 80% (user) vs 52% (non-user) – statistically significant; after 6 months of Papilocare use: 88% (user) vs 56% (non-user) – statistically significant

Repairing HPV cervical lesions in HPV patients (all risk levels) after 3 months of Papilocare use: 78% (user) vs 55% (non-user) – statistically significant; after 6 months of Papilocare use: 85% (user) vs 65% (non-user) – statistically significant

HPV clearance among HPV patients after 6 months of Papilocare use (daily for the first three weeks and every other day afterwards): 60% (user) vs 42% (non-user) – statistical significant not achieved

HPV clearance among HPV patients after 6 months of daily Papilocare use: 76% (user) vs 42% (non-user) – statistically significant; HPV clearance among high-risk HPV patients after 6 months of daily Papilocare use: 82% (user) vs 40% (non-user) – statistically significant

Normal Pap smear findings and concordant colposcopy observations after 6 months of Papilocare use: 85% (user) vs 65% (non-user) -statistically significant; normal Pap smear findings and concordant colposcopy observations after 6 months of Papilocare use among the high-risk HPV patients: 88% (user) vs 56% (non-user) -statistically significant

https://www.procarehealth.fr/resultats-cliniques

https://doi.org/10.1186/ISRCTN12928573

https://journals.lww.com/jlgtd/Fulltext/2021/04000/Efficacy_of_a_Coriolus_versicolor_Based_Vaginal.9.aspx

Leads to higher rate of repair for the HPV cervical lesions

Improves the rate of HPV clearance

Leads to repair of cervical epithelia

Restores normal microbiota

In some rare cases, inflammatory symptoms such as irritation, itching and/or burning sensation might be felt after the use of Papilocare. This type of reaction is more common in women with a very sensitive or significantly damaged genital area or with altered vaginal pH (e.g., post menopause, recent vaginal infections). One possible cause of the irritation is the difference between the alkaline vaginal pH of peri or post-menopause women and the pH of the product, which is 5.5. Another possible reason is an allergy to any of the ingredients. The symptom appears at the beginning of treatment and usually disappears along the usage of the product. If any of these symptoms appear, the treatment should be interrupted. If the symptom is severe or persistent, you should stop the use of the product consult your doctor.

The product is not tested among pregnant and breast-feeding women, so if you are in this situation, it is not recommended to use the product.

Paraben free

1 application per day, any time of the day for the first 21 days

1 application every other day for 5 months

Effect observed from the three month on

It is recommended to apply Papilocare® at bedtime.

  1. Lie down, remove the cap from the nozzle of the cannula (tube). Gently insert the nozzle completely into the vagina. Do not use if the canula is open or appears broken.
  2. If you find it helpful for insertion, you can squeeze out a small quantity of the gel and rub it around the tip of the cannula to lubricate it.
  3. Squeeze the container (from the bottom to the top) until it is empty, then gently remove the nozzle from the vagina while still squeezing the cannula, to avoid gel removal.
  4. Do not rinse.
  5. Discard the single-dose cannula.

It is possible that a small amount of the gel remains in the cannula after the use. However, it does not mean that you did not release a sufficient dose. 3ml of the gel is sufficient to cover the cervical-vaginal mucosa while the cannula contains 5ml. Please do not reuse the remaining gel, however.  The cannula might appear empty but this is due to the fact that it has a 10ml capacity for the content of 5ml.

Dr. Damián Dexeus
Specialist in gynecology and obstetrics. Women’s Health Institute Barcelona.

It is therefore hypothesised that through this multiple actions (of Papilocare) positively interfering with the three modifiable factors of the HPV clearance, this could facilitate the clearance of HPV and prevent its integration into cells.

Dr. Luis Serrano
Specialist in gynecology and obstetrics.
Policlínico HM Gabinete Velázquez, Madrid

Papilocare is an important step for patients with HPV infection, a therapeutic area that does not have many therapeutic solutions.

Dr. Margarita Riera
Catalan Health Institute
Principal Investigator in an independent study with Papilocare

I am very happy, delighted. (with Papilocare) I believe that we will continue to give Papilocare because, among other things, we have not seen any side effects in patients and that is a really important point.
Once the patient knows that she is carrying the papillomavirus, giving them the option of trying this product reassure them. They like the idea, they are quite compliant and certainly very happy when they see good results at the end of the treatment.

Dr. Javier Cortés
Senior Consultant in Gynecologic Oncology. Former President of the Spanish Association of Cervical Pathology and Colposcopy.

Although the research should continue, the barrier effect produced by Papilocare allows us to consider using it in patients with alterations of cervical epithelisation to hinder the integration of HPV and prevent cervical lesions appearance and progression.

1 review for Papilocare

There are no reviews yet.

Leave a review
Share your view on “Papilocare”

Your email address will not be published. Required fields are marked *

PAPILOCARE® has not been tested with pregnant women. Although there is no evidence to show that the use of PAPILOCARE® during pregnancy causes issues, we recommend that you consult your doctor before using the product.
The duration and final dosage of treatment with PAPILOCARE® VAGINAL GEL are always at the doctor's discretion, depending on the needs of each particular case.  In general, the manufacturer recommends that the product is used during a six months period before re-evaluation. This is due to the fact that the most comprehensive clinical data is based on a study in which patients were using the product for six months.
It is possible that a small amount of the gel remains in the cannula after use. However, it does not mean that you did not release a sufficient dose. 3ml of the gel is sufficient to cover the cervical-vaginal mucosa while the cannula contains 5ml. Please do not reuse the remaining gel, however.  The cannula might appear empty but this is due to the fact that it has a 10ml capacity for the content of 5ml.
"In some rare cases, inflammatory symptoms such as irritation, itching, and/or burning sensation might be felt after the use of Papilocare. This type of reaction is more common in women with a very sensitive or significantly damaged genital area or with altered vaginal pH (e.g., post-menopause, recent vaginal infections). One possible cause of the irritation is the difference between the alkaline vaginal pH of peri or post-menopause women and the pH of the product, which is 5.5. Another possible reason is an allergy to any of the ingredients. The symptom appears at the beginning of treatment and usually disappears along with the usage of the product. If any of these symptoms appear, the treatment should be interrupted. If the symptom is severe or persistent, you should stop the use of the product consult your doctor. The product is not tested among pregnant and breastfeeding women, so if you are in this situation, it is not recommended to use the product."
PAPILOCARE® contains lactic acid as an excipient. So if you are allergic to it, you should not use the product.

you may also like

Papilocare (21x5ml)

21 SINGLE-USE CANNULAS OF 5ML
(Most economical format)

World’s first treatment to prevent and treat cervical lesions caused by human papilloma virus (HPV)

Learn more about HPV and cervical lesions

Learn More
5.00 out of 5
58.53 (VAT included) Starter pack format available – Click Here

World's first medical product indicated for treatment of cervical lesions caused by HPV/ human papillomavirus